Over the last couple of years, we have witnessed the tremendous potential of adeno-associated virus (AAV)-based gene therapies. However, there have been a few high-profile safety issues that have occurred, including deaths associated with AAV vector gene therapies that have raised safety concerns among the public and regulators. Don’t miss this great primer on AAV-based gene therapies by Precision’s Deb Phippard and Phil Cyr, including basic background on the vectors, safety concerns, strategies to mitigate safety issues, and recent FDA safety meetings.
CLICK HERE to read the full article